FDA Draft Guidance - Best Practices for Developing Drug Trademarks

In late May, the FDA released a draft guidance document detailing its best practices for developing trademarks for drugs. The draft guidance, entitled Best Practices in Developing Proprietary Names for Drugs, can be found here.

Among other topics of interest to the pharmaceutical branding community, the draft guidance includes recommendations on how to pre-screen drug trademark candidates and what to consider when switching a drug from by-prescription only to over-the-counter.

This draft guidance is the last in a series of three that the FDA issued to assist the pharmaceutical industry in minimizing medication errors when designing and developing drug products. 

Comments on this draft guidance can be submitted to the FDA's Division of Dockets Management through July 28, 2014.

Topics:  Brand, Draft Guidance, FDA, Pharmaceutical Manufacturers, Prescription Drugs, Trademarks

Published In: Administrative Agency Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sterne, Kessler, Goldstein & Fox P.L.L.C. | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »